A shadow market for unapproved slimming drugs is being driven by social media fitness personalities and vendors on messaging platforms, based on new investigations.
Investigational Drug Gaining Traction Online
Retatrutide, which is still in clinical trials, is being advertised by social media influencers for its supposed fat-burning effects. Followers are urged to contact these accounts privately for source information, while also obtaining discount codes.
Active Trade on Social Networks
Separately, a robust market exists on Telegram, where communities with thousands of members share “before and after” images, administration instructions and assertions of rapid UK delivery. Vendors promote the substance there before directing buyers to other platforms for transactions.
Understanding The Experimental Drug
This medication is an investigational injection created by American pharmaceutical company Eli Lilly. The treatment targets three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials suggest it could assist individuals reduce up to a quarter of their body weight. Referred to as the “triple G”, the drug is being hailed digitally as the successor to Ozempic.
Medical Experts Voice Concerns
Nevertheless, doctors and chemists have cautions that the sale of what remains an unlicensed medication in the UK is a cause for concern and could result in individuals injecting products of uncertain source.
Some professionals said the popularity for the experimental drug could be connected to the rising price of approved slimming products such as Mounjaro.
Regulatory Position and Enforcement
Selling the unapproved drug on social media or Telegram is prohibited in the United Kingdom, as it is an unlicensed medication that must not be marketed or supplied for personal consumption under the British medical regulations.
Several influencers attempt to sidestep the rules by calling to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled drug, but promotion and supply can still breach pharmaceutical, advertising, and consumer regulations, potentially leading to fines, prosecution or imprisonment.
Service Response and Material Elimination
According to the social media company, the service has removed problematic content and banned related hashtags and query recommendations. The company stated it was committed to maintaining the platform safe and allocating resources in strengthening compliance measures.
Digital Trading Activities
Research also found communities with up to 9,000 members marketing retatrutide using the platform's built-in search feature, which operates like a online catalog. Typing “retatrutide” instantly displays channels with thousands of users, filled with photos of slimming results, positive testimonials and step-by-step instructions for mixing or injecting at residence.
Within minutes of entering one group, a seller shared contact information, where most transactions occur. The seller provided an guidebook and guaranteed shipping within two days. When asked whether the substance was genuine, one seller responded: “You can’t be sure.” Another provided a image of a alleged laboratory certificate. Not one asked about body mass, medical conditions or previous experience.
Item Information and Pricing
Within these communities, posts display black plastic packages with Royal Mail labels, claiming to contain new batches. One communication stated: “It took eight of us to load them this morning.”
Customers can choose between powder vials, mixed at residence with sterile water, or pre-filled injectors typically priced at 160 pounds for 20mg. When questioned how much time a injector should be used, sellers give contradictory responses ranging from a few weeks to “depends on your body”.
Service Moderation and Safety Actions
A spokesperson for Telegram stated it regularly moderated dangerous content on its platform including content that encouraged the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”.
Medical Professional Cautions
“Individuals are administering substances they can’t verify. Although the science behind retatrutide is sound, these digital products may not contain what they claim,” said Jason Murphy, the director of pharmaceutical services at a pharmacy service.
Dr Crystal Wyllie of Asda Online Doctor linked the increase in interest to recent price rises for approved weight-loss drugs such as Mounjaro. “With costs increasing, patients are using online platforms. But fake injections are highly dangerous. You can’t be certain what’s contained or whether the environment they were made in was sterile,” she explained.
Her team has previously encountered individuals harmed by self-injection from unverified suppliers. “We understand the frustration, but buying from messaging apps or communication platforms is taking chances with your health,” said the doctor. “These substances could be impure or improperly measured.”
Manufacturer Position
A spokesperson from the pharmaceutical company stated retatrutide was in third stage research studies and had not been evaluated or authorized by any government authority anywhere in the world. “Therefore at this time no one can sell [it] for human use,” they said, adding that any product “falsely representing itself as a Lilly investigational product not yet approved … may expose users to potentially significant health risks”.
